BioAge Labs (BIOA) vs Emergent BioSolutions (EBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 11.8% versus a loss of 28.7%. Emergent BioSolutions is the larger company by market cap ($355.8 million vs $281.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | EBS |
|---|---|---|
| Share price | $6.14 | $6.94 |
| Market cap | $281.81M | $355.84M |
| 1-day change | -1.92% | -1.84% |
| YTD return | -52.68% | -42.80% |
| 1-year return | +11.79% | -28.73% |
| 5-year return | — | -86.05% |
| Forward P/E | — | 6.63 |
| EPS (TTM) | $-2.39 | $-3.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $14.06 |
| 52-week low | $5.04 | $4.36 |
| Distance from 52-week high | -76.34% | -50.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +480.29% | +58.50% |
| Average volume | 913.77K | 1.16M |
| Shares outstanding | 45.90M | 51.27M |
| Employees | 60 | 900 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed EBS by 40.5 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
BIOA vs EBS FAQ
Which is bigger, BioAge Labs or Emergent BioSolutions?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $355.84M compared with $281.81M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or EBS?
BIOA returned +11.79% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Emergent BioSolutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.